Literature DB >> 2854056

The amino-terminal domain of the hepadnaviral P-gene encodes the terminal protein (genome-linked protein) believed to prime reverse transcription.

R Bartenschlager1, H Schaller.   

Abstract

A series of antisera directed against amino acid sequences from different segments of the duck hepatitis B virus (DHBV) P-gene were shown to immunoprecipitate DHBV DNA molecules that were covalently linked to the DHBV DNA terminal protein. Restriction analysis and sizing after protease treatment demonstrated that the P-gene proteins were bound to the 5'-end of the DHBV DNA minus-strand which was mapped to a G-residue in the centre of the repeat sequence DR1. Resistance to alkali treatment indicated a phosphodiester linkage to tyrosine between protein and DNA. Limited protease treatment prior to immunoprecipitation cleaved C-terminal P-proteins from the viral DNA, indicating that the terminal protein forms a separate domain encoded in the N-terminal part of the P-gene. Functional analysis of a deletion mutant confirmed the notion that a non-essential spacer separates the terminal protein from the polymerase domain residing in the C-terminal half of the P-gene. Thus, the major proteins required for hepadnaviral reverse transcription, namely the primer, DNA polymerase, and possibly also RNase H, appear to be synthesized as a polyprotein precursor which is at least initially linked as such to its first DNA product.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2854056      PMCID: PMC455131          DOI: 10.1002/j.1460-2075.1988.tb03315.x

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  24 in total

1.  Replication of the genome of a hepatitis B--like virus by reverse transcription of an RNA intermediate.

Authors:  J Summers; W S Mason
Journal:  Cell       Date:  1982-06       Impact factor: 41.582

2.  Protein covalently bound to minus-strand DNA intermediates of duck hepatitis B virus.

Authors:  K L Molnar-Kimber; J Summers; J M Taylor; W S Mason
Journal:  J Virol       Date:  1983-01       Impact factor: 5.103

3.  Genome-linked proteins of viruses.

Authors:  E Wimmer
Journal:  Cell       Date:  1982-02       Impact factor: 41.582

4.  Adenovirus DNA replication in vitro: characterization of a protein covalently linked to nascent DNA strands.

Authors:  M D Challberg; S V Desiderio; T J Kelly
Journal:  Proc Natl Acad Sci U S A       Date:  1980-09       Impact factor: 11.205

5.  Hepatitis B virus contains protein attached to the 5' terminus of its complete DNA strand.

Authors:  W H Gerlich; W S Robinson
Journal:  Cell       Date:  1980-10       Impact factor: 41.582

6.  Nucleotide sequence of a cloned duck hepatitis B virus genome: comparison with woodchuck and human hepatitis B virus sequences.

Authors:  E Mandart; A Kay; F Galibert
Journal:  J Virol       Date:  1984-03       Impact factor: 5.103

7.  The duck hepatitis B virus P-gene codes for protein strongly associated with the 5'-end of the viral DNA minus strand.

Authors:  V Bosch; R Bartenschlager; G Radziwill; H Schaller
Journal:  Virology       Date:  1988-10       Impact factor: 3.616

8.  DNA polymerase associated with human hepatitis B antigen.

Authors:  P M Kaplan; R L Greenman; J L Gerin; R H Purcell; W S Robinson
Journal:  J Virol       Date:  1973-11       Impact factor: 5.103

9.  Sequence homology between retroviral reverse transcriptase and putative polymerases of hepatitis B virus and cauliflower mosaic virus.

Authors:  H Toh; H Hayashida; T Miyata
Journal:  Nature       Date:  1983 Oct 27-Nov 2       Impact factor: 49.962

10.  Oligonucleotide-directed mutagenesis using M13-derived vectors: an efficient and general procedure for the production of point mutations in any fragment of DNA.

Authors:  M J Zoller; M Smith
Journal:  Nucleic Acids Res       Date:  1982-10-25       Impact factor: 16.971

View more
  85 in total

1.  Duck hepatitis B virus can tolerate insertion, deletion, and partial frameshift mutation in the distal pre-S region.

Authors:  J S Li; L Cova; R Buckland; V Lambert; G Deléage; C Trépo
Journal:  J Virol       Date:  1989-11       Impact factor: 5.103

2.  In vitro reconstitution of a functional duck hepatitis B virus reverse transcriptase: posttranslational activation by Hsp90.

Authors:  J Hu; D Anselmo
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

3.  An essential arginine residue for initiation of protein-primed DNA replication.

Authors:  J C Hsieh; S K Yoo; J Ito
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

Review 4.  Metabolism and function of hepatitis B virus cccDNA: Implications for the development of cccDNA-targeting antiviral therapeutics.

Authors:  Ju-Tao Guo; Haitao Guo
Journal:  Antiviral Res       Date:  2015-08-10       Impact factor: 5.970

Review 5.  Animal models and the molecular biology of hepadnavirus infection.

Authors:  William S Mason
Journal:  Cold Spring Harb Perspect Med       Date:  2015-04-01       Impact factor: 6.915

Review 6.  Nature and display of hepatitis B virus envelope proteins and the humoral immune response.

Authors:  A Alberti; W H Gerlich; K H Heermann; P Pontisso
Journal:  Springer Semin Immunopathol       Date:  1990

7.  Effects of insertional and point mutations on the functions of the duck hepatitis B virus polymerase.

Authors:  L J Chang; R C Hirsch; D Ganem; H E Varmus
Journal:  J Virol       Date:  1990-11       Impact factor: 5.103

8.  Evidence that less-than-full-length pol gene products are functional in hepadnavirus DNA synthesis.

Authors:  T T Wu; L D Condreay; L Coates; C Aldrich; W Mason
Journal:  J Virol       Date:  1991-05       Impact factor: 5.103

9.  Detection of an RNase H activity associated with hepadnaviruses.

Authors:  S M Oberhaus; J E Newbold
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

10.  Protein-primed terminal transferase activity of hepatitis B virus polymerase.

Authors:  Scott A Jones; Jianming Hu
Journal:  J Virol       Date:  2012-12-19       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.